Sriram Neelamegham



Sriram Neelamegham


Sriram Neelamegham


Research Topics

Biomedical engineering; cell biomechanics; vascular engineering

Contact Information

906 Furnas Hall

Buffalo NY, 14260

Phone: (716) 645-1200

Fax: (716) 645-3822

Biography Publications Teaching Research


  • PhD, Chemical/Biomedical Engineering, Rice University, 1996
  • B.Tech, Chemical Engineering, Indian Institute of Technology, 1991

Sriram Neelamegham is a Professor of Chemical & Biological Engineering, Biomedical Engineering and Medicine at the University at Buffalo, State University of New York. He received his Ph.D. in Chemical Engineering, with specialization in Bioengineering, from Rice University in 1995-96. After completed his post-doctoral training at the Baylor College of Medicine, he established his independent research laboratory at Buffalo in 1997. Prof. Neelamegham is well published with over 100 research manuscripts, book chapters and patents in diverse areas related to Chemical Engineering and Bioengineering.

He has made pioneering contributions in studies that describe the molecular mechanisms by which white blood cells (leukocytes) and platelets in human blood, interact with other vascular cells in the context of human inflammatory diseases. He has also contributed to our understanding of the mechanisms by which fluid shear controls the structure of a large blood protein called von Willebrand factor. This is a critical glycoprotein that regulates the rates of thrombosis and vessel occlusion in the stenosed arterial circulation and in artificial implants. More recently, he is interested in developing and applying Systems Biology principles for the study of biosynthetic steps that regulate cellular glycosylation. In such studies, high-throughput experimentation and mathematical modeling is performed to understand the interplay between various enzymes as they regulate glycan biosynthesis. The laboratory is focused on translating their basic science findings for human health benefit by: i. developing small molecule antagonists that target glycosylation and prevent inappropriate leukocyte adhesion at sites of inflammation, ii. designing glycoengineering strategies to target stem cells to sites where therapy is required, and iii. developing new glycan-engineered therapeutics to enhance the half-life and efficacy of human blood proteins.

Prof. Neelamegham is a recipient of the NIH Independent Scientist award, 2015 State University of New York Chancellor's Award for Excellence in Scholarship and Creative Activities, 2018 Schoellkopf medal from the Western New York American Chemical Society and is an Elected Fellow of the American Institute of Biological and Medical Engineering (AIMBE, 2012). He has served on NIH advisory panels, editorial boards of various journals and is currently the lead facilitator developing the Symbol Nomenclature for Glycans (SNFG) at the NCBI-glycans resource.